title: Conjunctival malt lymphoma successfully treated with single agent rituximab therapy.
authors.forename: Taflan
authors.initials: T
authors.lastname: Salepci
authors.forename: Mesut
authors.initials: M
authors.lastname: Seker
authors.forename: Ekrem
authors.initials: E
authors.lastname: Kurnaz
authors.forename: Derya Oztas
authors.initials: DO
authors.lastname: Guler
authors.forename: Ahmet
authors.initials: A
authors.lastname: Bilici
authors.forename: Faysal
authors.initials: F
authors.lastname: Dane
authors.forename: Mehmet
authors.initials: M
authors.lastname: Aliustaoglu
authors.forename: Elif Birtas
authors.initials: EB
authors.lastname: Atesoglu
authors.forename: Mahmut
authors.initials: M
authors.lastname: Gumus
authors.forename: Mustafa
authors.initials: M
authors.lastname: Yaylaci
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D003230:Conjunctival Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D018442:Lymphoma, B-Cell, Marginal Zone / Q000188:drug therapy*; D012074:Remission Induction; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab